We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Scientists Identify Gene Linked to Fatal Heart Condition

By Biotechdaily staff writers
Posted on 21 May 2002
A team of researchers from the Weizmann Institute of Science (Rehovot, Israel) and the Sheba Medical Center (Tel Aviv, Israel) has now identified the gene that causes polymorphic ventricular tachycardia (PVT). More...
This is a fatal heart condition, primarily affecting young children, that is characterized by a fast and irregular heartbeat, seizures, and in certain cases, sudden death.

As reported in the December 2001 issue of the American Journal of Human Genetics, researchers found that the disease is caused by a mutation in the gene known as Calsequestrin 2 (CASQ2), which plays a vital role in the contraction and relaxation of the heart. The mutation impairs the ability of the CASQ2 protein to attract and release calcium ions upon demand.

The current study focused on a Bedouin tribe in Northern Israel, where PVT had caused the death of nine children, in some cases from the same family. Initially, the researchers were faced with trying to identify the exact gene responsible for PVT from a possible 80 candidate genes. Fortunately, as the work progressed, information from the Human Genome Project became available. The newly mapped gene for CASQ2 emerged as a good prospect because this protein serves as a calcium ion reservoir in heart muscle cells. Indeed, only four months earlier a different research team had found that a mutation in the gene RYR2, which belongs to the same cellular pathway as CASQ2, also causes a form of PVT.

The researchers were able to confirm that the Bedouin children suffering from PVT had a mutation in their CASQ2 gene. While the mutation was caused by only a single base change, from G to C, in one of the DNA's nucleotides, this change caused the body to produce the positively charged amino acid histidine instead of negatively charged aspartic acid, which impairs the CASQ2 protein's ability to attract and release calcium ions, leading to heart failure.

"The new finding is expected to improve the screening for and treatment of this fatal disease, as well as opening a window to a better understanding of other heart conditions,” says Dr. Nili Avidan of the Weizmann Institute's Department of Molecular Genetics. "We believe that mutations in this and other biochemically related genes may lie behind a number of as yet largely unsolved heart disorders.”




Related Links:
Weizmann Institute of Science
Sheba Medical Center

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Chromogenic Culture System
InTray™ COLOREX™ ECC
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.